Press releases
25 June 2019, Zwingenberg

BRAIN AG sells its entire stake in Monteil Cosmetics International GmbH

  • BRAIN thereby withdraws from the loss-making segment of the B2C cosmetics business
  • Focus on growth in the product-scalable B2B product business of the BRAIN Group

BRAIN AG (together with its subsidiaries the “BRAIN Group” or “BRAIN”) has concluded an agreement with Wilde Cosmetics GmbH, Oestrich-Winkel, on the sale of all shares in the loss-making Monteil Cosmetics International GmbH (“Monteil”) held by BRAIN to Wilde Cosmetics GmbH. The transaction will be completed on 30 June 2019. The contracting parties have agreed not to disclose financial details.

Monteil Cosmetics International GmbH, based in Düsseldorf, is represented as a brand company in the cosmetics end customer business (B2C). It has been part of the BRAIN Group since 2011. Most recently, BRAIN AG held 68.3% of the Monteil shares, while Wilde Cosmetics GmbH acted as a minority shareholder. The sale of the loss-making investment will unburden the BRAIN Group both financially and in terms of capacity and allow it to concentrate fully on the further expansion of the product-scalable B2B business.

“The focus of the BRAIN Group is on growing the product business with industrial partners. The companies in the BRAIN Group are now fully specialized in R&D and B2B business. This is where we see the absolute strengths of the BRAIN Group, which we are continuously expanding”, says Dr. Jürgen Eck, CEO of BRAIN AG.

“We have taken a further step towards consistently implementing our strategy. The pure B2B cosmetics business is and will remain part of the growth strategy”, says Ludger Roedder, CBO of BRAIN AG.

“The sale of the Monteil shares has no impact on the forecasts of BRAIN AG for the current 2018/19 financial year. Rather, we confirm the objective of achieving a double-digit growth rate in total operating performance and improved EBITDA at Group level”, adds Manfred Bender, CFO of BRAIN AG.

About BRAIN

BRAIN Biotech AG is a leading European supplier of bio-based products and solutions such as enzymes and proteins, microbial production strains, natural compounds and biotechnological solutions for more sustainable industrial processes. The company focuses on the fields of nutrition, health and environment.

BRAIN Biotech AG is the parent company of the international BRAIN Biotech Group. The Group's business activities are divided into three segments: The BioProducts segment comprises the product business with specialty enzymes and other proteins, for which the Group operates fermentation facilities in the United Kingdom and production facilities in continental Europe and the United States. The BioScience segment offers research-intensive custom solutions based on enzyme technology, strain development, bioprocess development and natural product screening. The BioIncubator segment conducts its own R&D projects or those initiated with partners with high value-added potential. A particularly promising incubator project is the development of the Company's own CRISPR-based gene editing technology platform, which is currently being established and expanded by Akribion Genomics (in foundation planning).

Through its own R&D activities, BRAIN Biotech Group is continuously expanding its product portfolio in the field of specialty enzymes and small molecules. The latter are the starting point for screenings, e.g. for novel drug candidates for pharmaceutical applications.

BRAIN Biotech AG has been listed on the Prime Standard of the Frankfurt Stock Exchange since February 9, 2016 (ticker symbol: BNN; securities identification number: ISIN DE0005203947 / WKN 520394). The company employs approximately 330 people and generated revenues of EUR 55,3 million in the fiscal year 2022/23.

For more information, please visit: https://www.brain-biotech.com, LinkedIn, Threads and YouTube.

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN Biotech AG, and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance, and entail both known and unknown risks as well as uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Numerous factors exist that could influence the future performance of and future developments at BRAIN Biotech AG and the BRAIN Biotech Group. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, as well as other factors. BRAIN Biotech AG does not undertake any obligation to update or revise any forward-looking statements.

Share this page